X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.
Lead Product(s): IBI-343
Therapeutic Area: Oncology Product Name: IBI-343
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sotio
Deal Size: $740.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
Details:
Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: MacroGenics
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chong Kun Dang Pharm
Deal Size: $132.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 06, 2023
Details:
Amgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one Antibody Drug Conjugate (ADC) program.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
Details:
Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hummingbird Bioscience
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2023
Details:
Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Emergence Therapeutics
Deal Size: Undisclosed Upfront Cash: $360.0 million
Deal Type: Licensing Agreement September 06, 2022
Details:
The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.
Lead Product(s): Antibody-drug Conjugate Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: $176.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement June 30, 2022
Details:
Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-drug Conjugate.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: MacroGenics
Deal Size: $586.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
